Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer | British Journal of Cancer
Lung Pathway Group – Erlotinib in Non-Small Cell Lung Cancer (NSCLC)
Estrogen receptor β1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer
Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling | Science Translational Medicine
Erlotinib dose-adjusted for smoking status effective as first treatment for head and neck cancer - ecancer
Cytotoxic effect of erlotinib. Dose–response curves of LICR-HN2 (a),... | Download Scientific Diagram
Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878) - ScienceDirect
Dose dependent growth inhibition of lung cancer cell-lines by erlotinib... | Download Scientific Diagram
O-0006 Dose Escalation to Rash for Erlotinib Plus Gemcitabine in Patients with Metastatic Pancreatic Cancer: The Phase II RACHEL
Erlotinib Therapy in Non Small Cell Lung Cancer Patients - Survival of Patients on Reduced Erlotinib Doses M. Pesek 1, J. Krejci 1, J. Skrickova 2, P. - ppt download
Erlotinib Activates Different Cell Death Pathways in EGFR-mutant Lung Cancer Cells Grown in 3D Versus 2D Culture Systems | Anticancer Research
Hepatic Failure and Hepatorenal Syndrome Secondary to Erlotinib. Safety Reminder
Phase I/II Study of Erlotinib to Determine the Optimal Dose in Patients With Non‐Small Cell Lung Cancer Harboring Only EGFR Mutations - Takeda - 2020 - Clinical and Translational Science - Wiley Online Library
Safety and CSF distribution of high-dose erlotinib and gefitinib in patients of non–small cell lung cancer (NSCLC) with brain metastases | SpringerLink
Phase I Study of Oral Vinorelbine in Combination with Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Using Two Different Schedules | PLOS ONE
Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study | British Journal of Cancer
![PDF] Drug-Drug Interactions, Safety, and Pharmacokinetics of EGFR Tyrosine Kinase Inhibitors for the Treatment of Non–Small Cell Lung Cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/9e910d8d1951b8c8ce75da97d430cc24bb7492ac/4-Table2-1.png "PDF] Drug-Drug Interactions, Safety, and Pharmacokinetics of EGFR Tyrosine Kinase Inhibitors for the Treatment of Non–Small Cell Lung Cancer | Semantic Scholar")
PDF] Drug-Drug Interactions, Safety, and Pharmacokinetics of EGFR Tyrosine Kinase Inhibitors for the Treatment of Non–Small Cell Lung Cancer | Semantic Scholar
IJMS | Free Full-Text | Kinase-Inactivated EGFR Is Required for the Survival of Wild-Type EGFR-Expressing Cancer Cells Treated with Tyrosine Kinase Inhibitors
Frontiers | Phase II Trial of Erlotinib during and after Radiotherapy in Children with Newly Diagnosed High-Grade Gliomas
Cytotoxic effect of erlotinib. Dose–response curves of LICR-HN2 (a),... | Download Scientific Diagram
Erlotinib at a Dose of 25 mg Daily for Non-small Cell Lung Cancers with EGFR Mutations - ScienceDirect
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial - The Lancet
Systematic Approach Can Manage Erlotinib Skin Toxicity
